Liver-related morbidity and mortality is expanding in people living with HIV. Hepatocellular carcinoma (HCC), the third most lethal malignancy on a global scale, is a dominant complication of chronic liver disease and cirrhosis in patients with coexisting hepatitis. HIV infection further complicates the clinical heterogeneity of HCC, posing concurrent challenges stemming from the underlying immunological status of the patients and the ongoing need for combined antiretroviral therapy. In this article, we review the multiple clinical implications that characterize the multidisciplinary management of HCC in the context of HIV infection.
Introduction
Hepatocellular carcinoma (HCC) is the sixth commonest solid tumour worldwide, with more than 750 000 new cases per year [1] . Despite major advances in diagnosis and therapy, mortality is increasing, making HCC the third most lethal malignancy [2] : a figure that is in deep contrast to the generalized reduction of cancer-related mortality observed across a wide range of malignancies in the last decades [3] . Liver cirrhosis is the main predisposing factor for HCC, predating the diagnosis of cancer in more than 80% of the patients, with viral hepatitis, alcohol excess and nonalcoholic steatohepatitis being the most prevalent risk factors in the general population [4] .
In people living with HIV (PLHIV), coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) is common due to shared transmission modalities. With the extended life expectancy offered by combined antiretroviral therapy (cART), this patient subpopulation is at increased risk of long-term complications from chronic liver disease including HCC, for which the latency period from infection to cancer is measured in decades [4] .
Overall, HBV is the leading viral aetiologic factor for HCC, being responsible for more than 50% of the incident cases and more than 320 000 deaths from HCC/ year worldwide, justifying, for this reason, the listing of HBV as the second most harmful human carcinogen following tobacco [5] . HBV/HIV coinfection is more common in countries where HBV is endemic (i.e. where HBV prevalence is 8%), and studies in sub-Saharan Africa reveal that more than 80% of HIV-positive individuals are HBV carriers [6] , a deep contrast with low prevalence areas including North America and most European countries where coinfection rates drop to 10% [7] .
HCV is responsible for at least one-third of HCC cases worldwide, being a leading viral aetiologic factor in Western countries including North America, Northern and Western Europe and Australia [8] , where the prevalence of HCV coinfection ranges between 15 and 30% amongst PLHIV [9, 10] .
Although HIV infection alone is not sufficient to promote hepatocarcinogenesis [11] , the complex interaction with hepatitis is amongst the key factors justifying the increasing burden of HCC in influencing the morbidity and mortality of PLHIV [12] . In addition to its role in influencing the pathogenesis of HCC, HIV infection adds a further layer of complexity to the already heterogeneous process of prognostication and treatment allocation that characterizes the management of HCC.
Unlike most malignancies, the prognosis of HCC is in fact not solely dictated by the extent of anatomical spread of the tumour, but also by the degree of functional impairment that accompanies cirrhosis, the overall fitness of the patient reflected by the performance status score as well as raised tumour biomarkers including alfafoetoprotein (AFP) [13] . In HIV-associated HCC, the host's immune status and polypharmacy stemming from the need for lifetime cART insist as additional clinical determinants to be considered in the management of HCC, posing issues with regard to a well tolerated and appropriate provision of radical treatments including liver resection or transplantation as well as locoregional or systemic therapies in the more advanced stages of the disease [14] .
In this review, we summarize multiple complexities that link HIV infection with the pathogenesis and prognosis of HCC in patients with concurrent viral hepatitis and discuss how these may impact on treatment allocation in the multidisciplinary management of HCC.
The contribution of HIV to the pathogenesis of hepatocellular carcinoma Mechanisms of HIV-induced hepatocarcinogenesis It has long time been debated whether HIV infection alone might represent a risk factor for the development of HCC [15] . Although PLHIV have a higher incidence of HCC compared with non-HIV-infected individuals [12] , large-scale epidemiological evidence has confirmed the confounding effect of coinfection with hepatitis in shaping such risk [11] .
HIV exerts its cocarcinogenic effects in synergy with hepatotropic viral infection largely through immunodeficiency. Impairment of the natural CD4 þ and CD8 þ T-cell responses as well as the antigen presentation processes impact on both HBV and HCV viral kinetics, favouring unrestrained viral replication, hence a faster progression to fibrosis, cirrhosis and -ultimatelymalignancy [16] .
Although the risk of HCC is greater in patients with lower CD4 þ cell counts [17] , an increasing number of studies suggest that the risk of malignancy is not solely driven by the immunological status of the patient, a factor of greater consequence in the cART era, where reconstitution of a quantitatively normal CD4 þ cell count is achievable.
A key factor that influences the risk of HCC as well as its natural history in PLHIV is the type of underlying hepatotropic infection. The molecular mechanisms linking HBV and HCV infection to the risk of liver cancer are profoundly different and account as a significant source of heterogeneity in clinical outcomes regardless of HIV status.
HIV/hepatitis B virus coinfection Intracellular persistence of HBV, a partially doublestranded DNA virus, is a noncytopathic event to the hepatocytes and most of the necroinflammatory liver disease secondary by HBV infection is mediated by the host's immune response [18] . Active HBV replication induces cyclical phases of hepatocellular necrosis, inflammation and subsequent regeneration and the resulting cytokine-rich milieu, dominated by IL-6 and IL-22 signalling and further activation of NF-kB and STAT3 pathways [19] , which in turn confer survival advantage to chronically injured hepatocytes. Interestingly, higher serum levels of IL-6 were found to be predictive of worse liver function test in patients with HIV/HBV coinfection, suggesting a role for sustained inflammation in shaping the risk of progression to significant fibrosis in coinfected patients [20] . Chronic inflammation associates with persisting oxidative stress [21] , which acts by promoting direct DNA damage but also by modulating intracellular signalling, gene expression and cell adhesion by lipid and protein peroxidation [22] . To further hasten the onset of malignancy, amongst the four viral proteins encoded by the HBV genome, the protein X (HBx) acts as a pleiotropic transactivator of gene transcription, dysregulating multiple pathways involved in cell proliferation, apoptosis and immunity [23] . In HIV-positive individuals, HBx has been shown to facilitate HIV-1 transcription through binding of regulatory proteins including C/EBPb, CREB1 and CREB2, providing evidence of viral synergy [24] .
A peculiar feature of HBV is the potential to integrate within the host genome. In animal models, transcriptional activation of the N-myc oncogene due to insertional mutagenesis is a key initiating event [25] . In humans, the advent of DNA sequencing technologies has unveiled multiple susceptible loci in which HBV DNA integration is more common. These include, amongst others, the MLL4 locus in chromosome 19, coding for a histone methyl-transferase that epigenetically controls gene expression [26] and the telomerase reverse transcriptase (TERT) locus in chromosome 5, encoding for the telomerase reverse transcriptase, a DNA-interacting enzyme whose dysregulation is involved in the acquisition of replicative immortality [27] . It is thought that the direct genotoxic effect of HBV justifies the observation that patients with chronic hepatitis may develop HCC even in absence of cirrhosis, an phenomenon that carries clinical implications in the screening policies for HCC, although the majority of patients with HBV-induced HCC present with cirrhosis, especially in the context of HIV coinfection.
Hepatitis delta virus (HDV) stands as an additional viral determinant influencing the clinical outcomes of a proportion of HIV/HBV carriers. A recent study of 771 HIV/HBV coinfected patients from the Swiss HIV Cohort study has shown a prevalence of HDV infection of 15%, with 63% of patients displaying evidence of active HDV replication. HDV infection was strongly associated with liver-related mortality [hazard ratio (HR) 7.7, 95% confidence interval (CI) 3.1-18.9] and development of HCC (HR 9.3, 95% CI 3.0-23.6), highlighting the need for prevention, adequate screening and monitoring of a population that is at a significant higher risk of HCC [28] .
HIV/hepatitis C virus coinfection Unlike HBV, the oncogenic potential of HCV is thought to be predominantly indirect. HCV is an RNA virus and therefore lacks integration potential. Once chronic infection is established, the progression to cirrhosis usually develops in 20-30% of the patients over the course of 2-3 decades, with 2-4% of established cirrhotics progressing to HCC on a yearly basis [29] . Chronic inflammation of the liver parenchyma is a key element in the pathophysiology of HCV-induced HCC in which the activation of hepatic stellate cells (HSCs) and persistent recruitment of immune-inflammatory cells tightly link hepatic fibrogenesis with the risk of HCC [30] . A number of molecular pathways have been elucidated as mechanistic drivers of such relationship, and these include dysregulation of transforming growth factor-b (TGF-b), a key controller of HSC activation and extracellular matrix remodelling [31] , in combination with many other molecular drivers of cell survival and avoidance of apoptosis [32] . HIV can directly infect a wide range of liver stromal cells including Kupffer [33] and HSCs [34] promoting a synergistic profibrogenic effect via induction of NF-kB and reactive-oxygen species overproduction [35] as well as modulation of profibrogenic cytokines, including TGF-b [36] and a number of chemokine pathways [37] . The convergence of the proinflammatory pathways upregulated by HCV and HIV provides mechanistic evidence supporting the accelerated course of fibrosis observed in the context of coinfection.
Experimental evidence suggests that HCV viral proteins may promote HCC through chronic perturbation of intracellular signalling pathways within chronically inflamed hepatocytes. A number of mechanistic relationships have been established in vitro including for instance the inactivation of tumour suppressor genes p53 and Rb1 mediated by the core protein, NS3 and NS5A; the promotion of survival pathways such as RAF/MAPK/ ERK by E2, NS5A and NS5B as well as PI3K/AKT and b-catenin/Wnt by NS5A, the latter being also involved in enhancement of cell motility and acquisition of metastatic potential through epithelial-to-mesenchymal transition [38] .
A significant contribution to hepatocarcinogenesis in HCV-related chronic liver disease is mediated by the host immune response. A number of host-related factors have been discovered to affect the susceptibility to HCC by modulating the rate of progression from cirrhosis through a differential proliferation advantage or by immunemodulatory mechanisms. Polymorphic variants in the epidermal growth factor, a potent hepatocellular mitogen and cofactor for HCV entry [39] have emerged as a molecular determinant of HCC susceptibility [40] . A similar association has been found for major histocompatibility complex class I polypeptide-related sequence-A [41] and a related locus HCP5 [42] to further strengthen the importance of inflammation and immunity in the pathogenesis of HCC. Immune activation is differentially regulated as a result of underlying hepatotropic infection in PLHIV [43] . Studies on HIV/HCV-coinfected patients have shown dynamic changes in soluble markers reflective of antiviral immunity (soluble CD14, CD163, autotaxin and IL-6) following antiviral therapy for HCV, suggesting immune-modulation as a key pathogenic mechanism in HIV/HCV coinfection [44] .
Other mechanisms of HIV-induced carcinogenesis An increased susceptibility to oxidative stress within hepatocytes and nonparenchymal cells has been shown to worsen both alcohol-induced and drug-induced hepatotoxicity [36] , being potentially reversed by therapeutic inhibition of chemokine-receptors including maraviroc [45] , a chemokine receptor 5 antagonist shown to have HCC-preventing effects in animal models [46] .
Liver steatosis is common in PLHIV, with nonalcoholic fatty liver disease due to HIV infection itself, cART or lipodystrophy being an expanding determinant underlying the progression of liver disease [47] . In HCVcoinfected patients, the prevalence of steatosis can approach 70% [48] . The use of nucleoside reverse transcriptase inhibitors including zidovudine, didanosine or stavudine is particularly associated with hepatic steatosis secondary to mitochondrial toxicity [49] .
Amongst the factors influencing an accelerated course of liver fibrosis in PLHIV, the altered intestinal permeability induced by HIV infection through mucosal depletion of CD4 þ cells and altered epithelial function facilitates the translocation of microbial products including lipopolysaccharide, with secondary activation of an immuneinflammatory response dominated by IL-1, IL-6 and TNF-a [50] . Such chronic, unopposed cytokine release is thought to facilitate the progression of liver fibrosis, and studies in HIV/HCV-coinfected patients have shown Toll-like receptors 4 and 9 to be mechanistically important in driving fibrogenesis, especially through the concerted activation of nonparenchymal liver cells [51] . In aggregate, it is beyond doubt that the pathophysiologic contribution of HIV to hepatocarcinogenesis is multifactorial and not solely driven by immune-depression, but rather encompassing a complex interaction of viral, immune, metabolic and pharmacokinetic factors associated with the need for ongoing cART. For this reason, adequate control of risk factors for HCC should cover these domains in their entirety from careful appropriate tailoring of cART to an accurate control of hepatotoxins.
HIV-associated hepatocellular carcinoma: the magnitude of the problem In the context of a global rise in the incidence of HCC in the past four decades, where the diagnosis of HCC has increased by a four-fold factor in the general population [52] , the overall burden of HCC in PLHIV has evolved in parallel. Large-scale epidemiological data from the Veteran Affairs healthcare database, reflecting clinical data from a cohort of 24 000 patients/year receiving HIV care between 1996 and 2009, have in fact shown a 23-fold increase in the prevalence of HCC from 0.07 to 1.62%. Clinical factors significantly associated with the diagnosis of HCC in this cohort include HCV coinfection [10, 95% CI 6.1-16.5], HBV coinfection (OR 2.8, 95% CI 1.7-4.7), lower CD4 þ cell counts (OR 2.4, 95% CI 1.3-4.2) or advanced age (OR 1.0, 95% CI 1.0-1.1) [53] . Interestingly, such steep increase in the prevalence of HCC seems to be a natural reflection of a concurrent increase in the prevalence of cirrhosis, which is maximal in patients coinfected with HCV.
The clinical relevance of liver-related comorbidities has also strongly emerged from the Mortavic study, a multicentre, prospective, cross-sectional database of 26 000 patients that has prospectively recorded mortality data from 24 French centres since 1995. Analysis of mortality rates in PLHIV has revealed a progressive increase in liver-related events, where HCC has become the leading cause of death, being accountable for more than 40% of the events in the studied cohort. Strikingly, patients succumbing from liver-related causes displayed evidence of well controlled HIV with median CD4 þ cell counts of 349 cells/ml, and 43% had received prior therapy for HCV. These findings corroborate preclinical evidence showing the multifactorial progression of HIVassociated HCC and highlight the need for a comprehensive management of other risk factors beyond HIV and HCV control, especially in a population with high rate of alcohol excess (>40%) and HBV prevalence in excess of 25% [54] .
The clinical management of hepatocellular carcinoma: challenges of HIV infection
Screening for hepatocellular carcinoma In the vast majority of patients, the onset of HCC is a generally asymptomatic process. When symptoms are present, these are generally vague, including constitutional decline or relating to the progression of the underlying chronic liver disease [55] . For this reason, although it is reasonable practice to suspect HCC in any patient presenting with acutely decompensated chronic liver disease, the long latency of an asymptomatic phase predating the clinical onset of HCC makes such disease an ideal setting for screening [56] .
Landmark randomized controlled studies conducted in Chinese HBV carriers have proven the cost-effectiveness and survival benefit of 6 monthly ultrasound imaging of the liver associated with concurrent AFP measurement in reducing the HCC-related mortality by 38%, despite an overall adherence to the screening programme of approximately 58% [57] . In a concurrent randomized controlled study conducted in the Qidong county in China, AFP-based screening with a cut-off of 20 ng/ml had proven ineffective [58] , strengthening the view that ultrasound alone is an effective screening method. AFP is an oncofoetal protein often re-expressed in the context of liver regeneration and a proportion of early-stage tumours do not express AFP, which may justify its suboptimal role as a screening biomarker [59] . Shortening ultrasound periodicity to 3 months does not improve the detection rate of HCC in cirrhotic patients [60] .
Clinical guidelines identify patients with Child-Pugh A and B cirrhosis as the ideal population at risk for which active screening for HCC is worthwhile, whereas class C patients should only be considered as candidates for liver transplantation. Due to the direct genotoxic effect of HBV, noncirrhotic HBV carriers should be considered for screening if they display evidence of active hepatitis or strong family history of HCC. Similarly, patients with HCV-induced advanced liver fibrosis should be screened for HCC even in absence of cirrhosis [1] (Table 1) . Viral eradication is a modifiable risk factor for HCC, and a number of studies have shown achievement of a sustained virological response (SVR) following interferon-based treatment as protective factor in the development of HCC [61] . Retrospective data from patients with HCV/HIV coinfection have shown that HCC may occur despite prior achievement of SVR independently from HIV control with median times between SVR and HCC onset of 28 months, reinforcing the need for screening in individuals at risk of HCC [62] . Although use of direct-acting antivirals has resulted in eradication rates more than 90%, the occurrence of liver cancer is not reduced in effectively treated cirrhotic patients [63] , and some studies have postulated an increased risk of HCC due to disruption of immune surveillance [64] , although this effect has not been reproduced in independent cohorts [65] .
In chronic hepatitis B, systematic reviews have shown patients receiving nucleoside analogue therapy having significantly lower HCC incidence [66] . In a large prospective study of 1096 patients, efficacious treatment for HBV resulted in improved recurrence rates and survival following complete resection of early-stage HCC, with hepatic expression of carboxylic acidterminal truncated HBx protein, a truncated viral product known to affect HCC cell invasion, predicting for unfavourable recurrence-free survival in patients treated with antivirals [67] .
Despite the increasing burden of liver-related morbidity in PLHIV [16] , evidence is lacking with regard to the cost-effectiveness and mortality-reducing role of screening in this patient population [68] . The presence of coexisting HIV infection per se, therefore, does not change the clinical criteria for HCC screening that are based around the severity of underlying chronic liver disease. European guidelines, however, suggest 6 monthly liver ultrasound and serum AFP as optimal methods for testing HIV-infected patients with HCV-related cirrhosis [69] .
Staged-stratified management and influence of HIV on the natural history of hepatocellular carcinoma Treatment modalities for HCC include surgical options such as liver resection or transplantation; locoregional therapies including radiofrequency ablation, percutaneous ethanol injection or transarterial chemoembolization and radioembolization, whereas the medical management of HCC is limited to oral multitargeted tyrosine kinase inhibitor, sorafenib, with the recent addition of regorafenib in the second-line setting.
The allocation of each individual patient to the most appropriate treatment strategy is often challenging, and a degree of variation in treatment approaches is accepted based on the local availability and expertise of the multidisciplinary team.
To allow a standardized approach to the management of HCC, treatment guidelines promote the adoption of the Barcelona Clinic Liver Cancer (BCLC) staging system, originally developed in 1999 to take into account of the most significant prognostic domains affecting the survival of patients with HCC. In fact, unlike other solid tumours, overall survival is a composite endpoint in HCC due to the mutual influence stemming from the underlying impairment in liver functional reserve, the presence of complications relating to cirrhosis such as portal hypertension, the anatomic spread of the tumour as well as, more in general, the patients' performance status (Fig. 1) .
Due to the complex interaction between all these factors, not more than 40% of the patients presenting with HCC can be offered curative treatments, making the intent of treatment essentially palliative for the majority of cases.
A number of studies have attempted to evaluate whether the characteristics of HCC, its natural history and overall prognosis are significantly different depending on HIV status. This question has been mostly addressed retrospectively and based on data stemming from the experience of single, tertiary referral centres. Interestingly, most studies adopted a cross-sectional, case-control design in which patients with HCV monoinfection were adopted as control group, leaving the presence of other risk factors including HBV infection relatively underrepresented. The vast majority of studies have reproducibly identified liver functional reserve [12, 70] , radiologic staging including tumour size [12, 70, 71] and portal vein invasion [12] as strong predictors of patients' survival.
The question as to whether HIV status modifies the biologic features and the clinical course of HCC has been matter of contention, with previous studies having highlighted inconsistent results. In coinfected patients, HCC is often diagnosed at an earlier age [72] due to a shorter interval between infection with HIV/hepatitis and the development of advanced fibrosis [73] . In terms of survival outcomes following the diagnosis of HCC, initial studies comparing cohorts matched by HIV status had originally reported a significantly shorter survival in HIV-infected patients [12] . However, treatment status is likely to have influenced the study by Puoti et al. [12] , in which 60% of the patients received no active anticancer treatment, and only 5% received potentially curative interventions. The multicentre study by Berretta et al. [71] , which retrospectively evaluated outcomes of 104 HIV-positive and 484 HIV-negative HCC patients, revealed HIV-infected individuals to have worse prognosis despite lower BCLC stage, younger age and better performance status as a likely result of less-aggressive retreatment approach at disease recurrence.
With the progressive diffusion of standardized screening and treatment strategies including the wider adoption of the BCLC staging algorithm from the early 2000s [74] , HIV status lost its independent prognostic influence in subsequent studies, as a likely result of the expanded access to active anticancer therapies of patients with optimally controlled HIV infection [70] .
Interestingly, in a large, retrospective, multicentre casecontrol study featuring 62 predominantly HCV-coinfected individuals with HIV-associated HCC, neither the presence nor the activity of HIV infection influenced outcome in the overall patient population, whereas undetectable plasma HIV RNA but not CD4 þ cell counts predicted for longer survival in people who did not receive active treatment for HCC, suggesting disease-modulating effects from cART through adequate suppression of viral replication and prevention of further fibrosis [75] .
In the cART era, the overall equivalence in survival outcomes from HCC regardless of HIV status is somewhat reinforced by a number of studies that investigated clinical outcomes as a function of treatment modality.
There is a paucity of reports to describe clinical outcomes of patients with HIV-associated HCC treated with resection or transplantation [76] . Although originally contraindicated [14] , HIV infection no longer represents a specific barrier for orthotopic liver transplantation (OLT) provided viral load suppression and adequate CD4 þ cell count (150 cells/ml) are achieved. Numerous case series demonstrate similar survival outcomes in patients matched for underlying liver functional reserve scores [77, 78] . However, the finding that HIV-coinfected individuals might suffer from increased mortality rates on the waiting list for OLT [79] reinforces the message that this subpopulation is characterized by an accelerated course to end-stage liver disease. Prospective evidence needs to be obtained for the use of locoregional therapies as downstaging techniques in an attempt to decrease dropout rates and enhance the survival of HIV-coinfected HCC patients.
Advanced HCC, for which sorafenib, a multitargeted inhibitor of Raf, PDGF-R and VEGF-R is the only approved first-line systemic treatment option [80] , poses an equally important set of challenges stemming from the need for careful therapeutic drug monitoring due to underlying liver dysfunction that accompanies cirrhosis and the pharmacokinetic complexities induced by concomitant cART. In addition, the potential of synergistic toxicity with cART in a palliative patient population in which treatment-induced survival benefit amounts to less than 3 months is an equally important concern [81] .
The evidence in this field is unfortunately limited to small case series. An Italian study of 27 patients shows that sorafenib therapy is deliverable in HIV-infected HCC with median overall survival reported at 12.8 months, a nondissimilar figure from that of preregistrative trials [82] .
Conclusion
The survival benefit derived from the improved medical management of patients with HIV infection has changed the pattern of mortality, reducing the proportion of patients who succumb from hepatic decompensation in the context of coinfection with viral hepatitis and increasing the proportion of those who develop HCC as a result. Similarly, the improved control over opportunistic infections in the cART era has reduced significantly a previously predominant element to influence patient's morbidity and mortality.
Mechanistic research has highlighted the numerous molecular complexities underlying the pathogenesis and progression of HCC in the context of HIV coinfection, which translate into a significant risk of developing HCC despite having achieved HCV clearance or adequate HIV control. Although research efforts are ongoing to dissect the molecular and clinical heterogeneity of HIV-associated HCC in an attempt to make screening, diagnosis and treatment algorithms personalized to the needs and clinical features of this patient population, the limited evidence currently available, mostly originating from retrospective studies, still forces clinicians to formulate their clinical decision-making based on evidence extrapolated from studies in HIVnegative individuals. Retrospective evidence has confirmed that the prognostic validity of the BCLC staging system extends to patients with HIV coinfection [71, 72] , suggesting the suitability of a stage-stratified management approach irrespective of HIV status.
With HIV infection being a significant barrier to the enrolment of cancer patients into early-phase clinical trials [83] , the chances of detecting early efficacy signals from novel investigational medicinal products are reduced in HIV-associated HCC, a matter of greater consequence in a disease in which targeted anticancer therapies and immunotherapy has led to significant improvements in the medical management of HCC.
With the increasing complexity of therapeutic options in viral hepatitis and HCC, including directly acting antiviral therapies for HCV, novel systemic anticancer therapies [84] and immune-checkpoint inhibitors for HCC [85] , concerted efforts insisting on the prevention, screening and stage-stratified management of HIVassociated HCC requires optimal integration of knowledge and expertise across HIV medicine, hepatology and oncology to maximize survival outcomes in this highly lethal malignancy.
